> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# IQVIA Cuts Trial Backlog By $2.1 Billion, Then Refinances 5.0% Notes With 6.375% Debt
- URL: https://www.bullished.co/iqvia-cuts-trial-backlog-by-2-1-billion-then-refinances-5-0-notes-with-6-375-debt-10aa97a5/
- Published: 2026-10-27T21:25:52.000Z
- Updated: 2026-10-27T21:25:52.000Z
- Description: The clinical research firm's backlog fell to $32.6 billion after it dropped inactive trials, while new 2034 notes carry a higher coupon.
- Author: Matteo Parrino
- Tags: SEC Filings, IQV, Industry: Healthcare

[IQVIA](https://www.bullished.co/tag/iqv/), which runs clinical trials for drugmakers and sells healthcare data, said in its third-quarter [10-Q](https://www.sec.gov/Archives/edgar/data/0001478242/000162828026067646/iqv-20260930.htm?ref=bullished.co) that it removed $2.1 billion of inactive trials from its research backlog, leaving $32.6 billion at September 30\. In the same period it issued $2,000 million of 6.375% notes to retire 5.0% notes that matured in October.

## A backlog reset, not a results change

Research & Development Solutions' contracted backlog stood at $32.6 billion on September 30, against $34.0 billion (recast for segment changes) at December 31, 2025\. The 10-Q says IQVIA refined its assessment criteria to reflect currently available information on expected future activity in inactive trials, which produced the $2.1 billion reduction.

The [earnings release](https://www.sec.gov/Archives/edgar/data/0001478242/000162828026067406/iqv-q3x2026earningspressre.htm?ref=bullished.co) says the adjustment has no impact on historical results, 2026 guidance, book-to-bill or next-twelve-month revenue from backlog. The company expects about $9.4 billion of backlog to convert to revenue over the next twelve months, which it put at growth of 10% year over year.

Remaining performance obligations, a related measure that excludes unperformed contracts the customer can cancel at will, are now about $34.2 billion. Revised quarter-end assumptions for some clinical research contracts lowered that figure. About 30% is expected to be recognized in twelve months and about 90% over five years.

## Cheaper notes out, pricier notes in

On September 23, IQVIA sold $2,000 million of 6.375% senior notes due 2034\. Part of the proceeds went into an irrevocable deposit that discharged its 5.0% notes due October 2026, which matured and were redeemed in full on October 9\. The rest repaid part of its revolving credit borrowings and covered fees.

The filing shows current portion of long-term debt at $1,244 million at September 30, down from $1,840 million at December 31, 2025\. Total debt principal was $16,172 million, up from $15,800 million. Interest expense for the third quarter was $203 million, against $189 million a year earlier, which the company attributes to higher debt balances.

In June the company also issued €950 million of 4.625% notes due 2033.

## Quarter and guidance behind it

Third-quarter revenue rose 8.0% to $4,428 million, and [diluted earnings per share](https://wtop.com/national/2026/10/iqvia-q3-earnings-snapshot/?ref=bullished.co) were $2.10\. R&D Solutions net new bookings were $3.2 billion, up 15%. The company raised full-year 2026 guidance for revenue, adjusted EBITDA and adjusted diluted earnings per share, with revenue now $17,350 million to $17,500 million.

IQVIA's market value was $45.0 billion in Tuesday trading.

IQVIA holds an Investor Day on December 1, when management will update investors on the business.

### Sources

- [10-Q Filing — IQVIA Holdings (IQV)](https://www.sec.gov/Archives/edgar/data/0001478242/000162828026067646/iqv-20260930.htm?ref=bullished.co) — SEC EDGAR
- [10-Q Filing — IQVIA Holdings (IQV), Q2 FY2026 filed 2026-07-28 (comparison basis)](https://www.sec.gov/Archives/edgar/data/0001478242/000162828026050211/iqv-20260630.htm?ref=bullished.co) — SEC EDGAR
- [Earnings release (8-K Item 2.02, iqv-q3x2026earningspressre.htm) — IQVIA Holdings, filed 2026-10-27](https://www.sec.gov/Archives/edgar/data/0001478242/000162828026067406/iqv-q3x2026earningspressre.htm?ref=bullished.co) — SEC EDGAR
- [IQVIA Non-GAAP EPS of $3.34 beats by $0.06, revenue of $4.43B beats by $60M (IQV:NYSE) | Seeking Alpha](https://seekingalpha.com/news/4657753-iqvia-non-gaap-eps-of-3%5F34-beats-by-0%5F06-revenue-of-4%5F43b-beats-by-60m?ref=bullished.co) — seekingalpha.com
- [IQVIA Holdings (IQV) Surpasses Q3 Earnings and Revenue Estimates](https://finance.yahoo.com/healthcare/articles/iqvia-holdings-iqv-surpasses-q3-111503096.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance
- [IQVIA Holdings Inc. Q3 2026 Earnings Call Summary](https://finance.yahoo.com/healthcare/articles/iqvia-holdings-inc-q3-2026-175019116.html?ref=bullished.co) — Yahoo Finance
- [IQVIA stock gains as R&D Solutions drive Q3 beat (IQV:NYSE) | Seeking Alpha](https://seekingalpha.com/news/4657864-iqvia-stock-gains-rd-solutions-drive-q3-beat?ref=bullished.co) — seekingalpha.com
- [IQVIA: Q3 Earnings Snapshot – WTOP News](https://wtop.com/national/2026/10/iqvia-q3-earnings-snapshot/?ref=bullished.co) — wtop.com

### More on IQVIA Holdings

- [IQVIA Has Deployed 415 AI Agents, CEO Says, But Sees No Price Cuts From Pharma](https://www.bullished.co/iqvia-has-deployed-415-ai-agents-ceo-says-but-sees-no-price-cuts-from-pharma-0a9aebdf/)
- [IQVIA CEO Says He Believes It Won Big In Pharma Contract Reshuffle, While Smaller Rivals 'Lost Out'](https://www.bullished.co/iqvia-ceo-says-he-believes-it-won-big-in-pharma-contract-reshuffle-while-smaller-rivals-bfaafad5/)
- [IQVIA Raises 2026 Outlook As Clinical Bookings Climb 15% To $3.2 Billion](https://www.bullished.co/iqvia-raises-2026-outlook-as-clinical-bookings-climb-15-to-3-2-billion-d290278d/)

[All IQVIA Holdings (IQV) coverage →](https://www.bullished.co/tag/iqv/)